Monitoring and treatment of iron overload: State of the art and new approaches

Seminars in Hematology

Volumn 42, Issue 2 SUPPL. 1, 2005, Pages

  Porter, J B ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; HEMOSIDERIN;

AGRANULOCYTOSIS; ANEMIA; ARTHRALGIA; BIOLOGICAL MONITORING; BIOMAGNETISM; BLOOD TRANSFUSION; BONE MARROW TOXICITY; CHELATION THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EAR DISEASE; ENZYME ASSAY; FERRITIN BLOOD LEVEL; GROWTH DISORDER; HEART DISEASE; HUMAN; INTOXICATION; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; KIDNEY DISEASE; LEUKEMIA; LIVER BIOPSY; MEDICAL ASSESSMENT; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TECHNIQUE; TREATMENT PLANNING;

EID: 15744397395     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2005.01.004     Document Type: Conference Paper

References (52)

1. M.B. Agarwal, S.S. Gupte, C. Viswanathan Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia Indian trial Br J Haematol 82 1992 460 466
2. L.J. Anderson, S. Holden, B. Davis Cardiovascular T2-star (T2* (*)) magnetic resonance for the early diagnosis of myocardial iron overload Eur Heart J 22 2001 2171 2179
3. L.J. Anderson, B. Wonke, E. Prescott Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia Lancet 360 2002 516 520
4. E. Angelucci, G.M. Brittenham, C.E. McLaren Hepatic iron concentration and total body iron stores in thalassemia major N Engl J Med 343 2000 327 331
5. Y. Aydinok, G. Nisli, K. Kavakli Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major Br J Haematol 106 1999 252 253
6. K. Balveer, K. Pyar, B. Wonke Combined oral and parenteral iron chelation in beta thalassaemia major Med J Malaysia 55 2000 493 497
7. G.M. Brittenham, A.R. Cohen, C.E. McLaren Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major Am J Hematol 42 1993 81 85
8. G.M. Brittenham, D.E. Farrell, J.W. Harris Magnetic-susceptibility measurement of human iron stores N Engl J Med 307 1982 1671 1675
9. G.M. Brittenham, P.M. Griffith, A.W. Nienhuis Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major N Engl J Med 331 1994 567 573
10. M. Cappellini Clinical overview of ICL670A 2003 Presented at the 16th Annual Meeting of the International BioIron Society, Bethesda, MD, May 3-9
11. A. Ceci, P. Baiardi, M. Felisi The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients Br J Haematol 118 2002 330 336
12. V.P. Choudhry, H.P. Pati, A. Saxena Deferiprone, efficacy and safety Indian J Pediatr 71 2004 213 216
13. A. Cohen, R. Galanello, A. Piga A multi-center safety trial of the oral iron chelator deferiprone Ann N Y Acad Sci 850 1998 223 226
14. A.R. Cohen, R. Galanello, A. Piga Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone Blood 102 2003 1583 1587
15. A.R. Cohen, R. Galanello, A. Piga Safety profile of the oral iron chelator deferiprone A multicentre study Br J Haematol 108 2000 305 312
16. R.R. Crichton, F. Roman, F. Roland Iron mobilization from ferritin by chelating agents J Inorg Biochem 13 1980 305 316
17. B.A. Davis, C. O'Sullivan, P.H. Jarritt Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major Blood 104 2004 263 269
18. B.A. Davis, J.B. Porter Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia Blood 95 2000 1229 1236
19. B.A. Davis, J.B. Porter Results of long term iron chelation treatment with deferoxamine Adv Exp Med Biol 509 2002 91 125
20. G.C. Del Vecchio, E. Crollo, F. Schettini Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting Acta Haematol 104 2000 99 102
21. R. Fischer, F. Longo, P. Nielsen Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major Application of SQUID biomagnetic liver susceptometry Br J Haematol 121 2003 938 948
22. V. Gabutti, A. Piga Results of long-term iron-chelating therapy Acta Haematol 95 1996 26 36
23. R. Galanello, A. Piga, D. Alberti Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia J Clin Pharmacol 43 2003 565 572
24. Y. Gandon, D. Olivie, D. Guyader Non-invasive assessment of hepatic iron stores by MRI Lancet 363 2004 357 362
25. S. Gomber, R. Saxena, N. Madan Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children Indian Pediatr 41 2004 21 27
26. J.M. Gutteridge, B. Halliwell Iron toxicity and oxygen radicals Baillieres Clin Haematol 2 1989 195 256
27. R.C. Hider, G. Kontoghiorghes, J. Silver Pharmaceutical compositions UK Patents GB 2118176A 1982
28. A.V. Hoffbrand, F. Al Refaie, B. Davis Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients Blood 91 1998 295 300
29. P.D. Jensen, F.T. Jensen, T. Christensen Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine indication of close relation between myocardial iron content and chelatable iron pool Blood 101 2003 4632 4639
30. P.D. Jensen, F.T. Jensen, T. Christensen Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine A study in adult patients with acquired anemias Blood 101 2003 91 96
31. C.J. Kellenberger, M. Schmugge, T. Saurenmann Radiographic and MRI features of deferiprone-related arthropathy of the knees in patients with beta-thalassemia AJR Am J Roentgenol 183 2004 989 994
32. G.N. Lucas, B.J. Perera, E.A. Fonseka Experience with the oral iron chelator deferiprone in transfusion-dependent children Ceylon Med J 47 2002 119 121
33. A. Maggio, G. D'Amico, A. Morabito Deferiprone versus deferoxamine in patients with thalassemia major A randomized clinical trial Blood Cells Mol Dis 28 2002 196 208
34. P. Mazza, B. Amurri, G. Lazzari Oral iron chelating therapy A single center interim report on deferiprone (L1) in thalassemia Haematologica 83 1998 496 501
35. F.H. Mourad, A.V. Hoffbrand, M. Sheikh-Taha Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients Br J Haematol 121 2003 187 189
36. H. Nick, A. Wong, P. Acklin ICL670A Preclinical profile Adv Exp Med Biol 509 2002 185 203
37. E. Nisbet-Brown, N.F. Olivieri, P.J. Giardina Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia A randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 361 2003 1597 1602
38. N.F. Olivieri, G.M. Brittenham Iron-chelating therapy and the treatment of thalassemia Blood 89 1997 739 761
39. N.F. Olivieri, G.M. Brittenham, D. Matsui Iron-chelation therapy with oral deferiprone in patients with thalassemia major N Engl J Med 332 1995 918 922
40. N.F. Olivieri, G.M. Brittenham, C.E. McLaren Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major N Engl J Med 339 1998 417 423
41. N.F. Olivieri, D.G. Nathan, J.H. MacMillan Survival in medically treated patients with homozygous beta-thalassemia N Engl J Med 331 1994 574 578
42. A. Piga, C. Gaglioti, E. Fogliacco Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major A retrospective analysis Haematologica 88 2003 489 496
43. P. Pootrakul, P. Sirankapracha, J. Sankote Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand Br J Haematol 122 2003 305 310
44. J.B. Porter Practical management of iron overload Br J Haematol 115 2001 239 252
45. J.B. Porter, R.D. Abeysinghe, L. Marshall Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy Blood 88 1996 705 713
46. J.B. Porter, E.R. Huehns The toxic effects of desferrioxamine Baillieres Clin Haematol 2 1989 459 474
47. T. Sergejew, P. Forgiarini, H.P. Schnebli Chelator-induced iron excretion in iron-overloaded marmosets Br J Haematol 110 2000 985 992
48. T.G. St Pierre, P.R. Clark, W. Chua-anusorn Non-invasive measurement and imaging of liver iron concentrations using proton magnetic resonance Blood 105 2005 855 861
49. P. Tondury, A. Zimmermann, P. Nielsen Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients Br J Haematol 101 1998 413 415
50. I.R. Wanless, G. Sweeney, A.P. Dhillon Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia Blood 100 2002 1566 1569
51. B. Wonke, C. Wright, A.V. Hoffbrand Combined therapy with deferiprone and desferrioxamine Br J Haematol 103 1998 361 364
52. K.H. Wu, J.S. Chang, C.H. Tsai Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major Ann Hematol 83 2004 471 473